<div id="readability-page-1"><div><p>ICON plc released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East.</p><p>ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&amp;D priorities since its last survey in 2023. It positions China's presence as a positive signal for the global industry, with the findings highlighting how Western biotechs must adapt to maintain competitiveness and drive innovation. Funding remains a key challenge and 41% of organizations are actively seeking additional R&amp;D funding, a 27% increase since 2023, highlighting ongoing financial pressures across the industry.</p><p>Globally, the top three sources of funding are unchanged: large pharma partnerships, venture capital (VC), and government grants. However, the survey shows how VC funds have expanded their focus, with APAC biotechs stating VC funding was 60% of their current funding source versus 32% for US and 30% for Europe. This is leading some biotechs to explore innovative funding sources and ICON highlights the emerging models being increasingly adopted, including royalty financing, carve-outs, and crowdfunding.</p><p>Since the last survey, access to talent is becoming more of a concern. This was more pronounced in APAC where responders were almost three times as likely to list talent shortages as having operational impact as their global counterparts (47% vs 18% in the US and 17% in Europe). The survey reveals leading next-generation modalities; notably, cell therapy has overtaken small molecules and is now most prominent, making up 40% of organizations' pipelines.</p><p>Antibody drug conjugates (ADCs) and microbiome therapies are not far behind at 31%. Therapeutic focus areas have also evolved since the last survey findings, with neurology (44%), cardiovascular (39%), and immune disorders (32%) now outpacing a previous dominance in oncology. Despite the multiple macro challenges they face, the biggest risk to biotechs' operations is the complexity of drug development.</p><p>Almost three quarters of respondents (73%) ranked this among their top five micro factorsposing the greatest risk to their organisation's operations. The survey highlighted how biotech companies are increasingly embracing digital technologies to improve operations, with 76% of respondents anticipating AI and other technologies will significantly accelerate R&amp;D processes within the next two years. When asked which factors have the most potential to accelerate drug development, 41% of respondents selected AI-enabled asset selection in drug discovery, an increase from 26% in 2023.</p><p>ION's separate survey of China-based biotechs, was based on 100 respondents. The findings highlighted that the challenges China-based biotechs face align with their global counterparts, most notably funding, and the complexity of drug development and regulations. Cardiovascular and oncology remain the top therapeutic focus areas in China, in contrast to the global shift toward neurology.</p><p>However, cell therapy, microbiome therapies, and ADCs dominate pipelines across all regions. Respondents in China also report less concern about geopolitical developments and greater confidence in investment and product success.</p></div></div>

ICLR

<p>ICON plc 的調查揭示了全球生物技術趨勢，突顯亞太地區的投資增長和中國的積極影響。資金挑戰依然存在，41% 的人尋求更多的研發資金。風險投資在亞太地區具有重要意義。人才短缺是一個令人擔憂的問題，尤其是在亞太地區。細胞治療在研發管道中處於領先地位，神經學、心血管和免疫疾病也受到關注。藥物開發的複雜性是一個主要風險，但人工智能等數字技術預計將加速研發。中國的生物技術挑戰與全球趨勢一致，地緣政治擔憂較少，投資信心強勁</p>

ICON plc 發佈了兩項關於生物技術行業的調查結果